Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Keywords

PembrolizumabMedicineLung cancerInternal medicineDosingConfidence intervalLogistic regressionAdverse effectOncologyResponse Evaluation Criteria in Solid TumorsCancerUrologyGastroenterologySurgeryPhases of clinical researchClinical trialImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more

2015 The Lancet 6378 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

Publication Info

Year: 2016
Type: article
Volume: 27
Issue: 7
Pages: 1291-1298
Citations: 157
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

157

OpenAlex

Cite This

APA Style

                            
                                
                                    Manash Chatterjee, 
                                
                                    David C. Turner, 
                                
                                    Enriqueta Felip
                                
                                et al.
                            
                            (2016). 
                            Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. 
                            Annals of Oncology
                            , 27
                            (7)
                            , 1291-1298.
                            https://doi.org/10.1093/annonc/mdw174
                        

Identifiers

DOI: 10.1093/annonc/mdw174